Exendin-4 decreases amphetamine-induced locomotor activity.
about
The central GLP-1: implications for food and drug rewardLong-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamusMoving beyond energy homeostasis: new roles for glucagon-like peptide-1 in food and drug rewardObesity and addiction: neurobiological overlapsGut-brain peptides in corticostriatal-limbic circuitry and alcohol use disordersRole of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapyThe glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in miceThe Anorexigenic Peptide Neuromedin U (NMU) Attenuates Amphetamine-Induced Locomotor Stimulation, Accumbal Dopamine Release and Expression of Conditioned Place Preference in MiceThe glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodentsThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trialGut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and rewardThe glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.Pre-existing differences in motivation for food and sensitivity to cocaine-induced locomotion in obesity-prone rats.PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced BehaviorExendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in miceGlucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.Central administration of the anorexigenic peptide neuromedin U decreases alcohol intake and attenuates alcohol-induced reward in rodents.GLP-1 analog attenuates cocaine reward.GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
P2860
Q21129358-06AB61FD-F0A7-40AE-B8F8-E05796CC6685Q26749191-76D0C792-C8CD-4991-B246-6BF4F4DA0DF4Q26826926-2A8CF494-5600-4DB8-9401-561741E7F0ABQ26827446-A59C7BB1-0640-49D2-BA21-E298D4E828C4Q27014840-02B6FCA8-7A76-44BD-93FD-178953130BC1Q28109507-E8F1B43B-DA12-44D9-A5AE-51191068CF41Q28534678-FC7477D1-8AD4-4E94-A4ED-16AAD390DCCFQ28551732-0AEE6FF0-0AA6-494E-94EC-46DAA44ED8D5Q28598004-EE7E253C-17CA-4D16-88C6-4ED83ACBB12EQ30596646-5E09563A-1FEF-4D6E-A7B4-29011492BE99Q34644655-7478692D-85A2-4F39-94F1-1A541F1068C4Q34685472-56C3AF54-0A16-4C63-B735-B0C9BAB7CD11Q35035127-3E4E35B1-AB39-4A0E-9BD2-444A07BB0339Q35813107-8616C2A2-F9F8-4E6F-89BE-2C0734F1D413Q36249101-24E62085-3E42-4D58-B060-B9A4ECB2515CQ36339320-9527D84A-6C9C-43D2-80B5-C6BD1C7E92BFQ36343957-BF9FF5ED-EDB0-4477-BA82-E1F74F9E5AF2Q36821806-022C94BF-1819-4DDE-AB75-40302F4AC96AQ37179909-FC40FA96-71A9-43CC-B51E-6032A7C15E41Q37349843-F9A9470F-8D4B-4CDD-88C2-7009874ECC3BQ39206330-5DBD09AE-68DA-4ABA-8784-506A8AC38934Q40105900-A53BD31D-A6EA-4301-BB81-7BA2544C3434Q42251573-1F380CCB-B261-480A-9583-85C9B62FF353Q48254506-5EF6FB20-7622-4BE2-8635-5B70112FD76CQ51744991-F4C692BF-07BC-4D98-85E2-C0ED951B5F5EQ52685416-27224ABB-CECE-467C-A8E7-4358AC07A71C
P2860
Exendin-4 decreases amphetamine-induced locomotor activity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Exendin-4 decreases amphetamine-induced locomotor activity.
@ast
Exendin-4 decreases amphetamine-induced locomotor activity.
@en
type
label
Exendin-4 decreases amphetamine-induced locomotor activity.
@ast
Exendin-4 decreases amphetamine-induced locomotor activity.
@en
prefLabel
Exendin-4 decreases amphetamine-induced locomotor activity.
@ast
Exendin-4 decreases amphetamine-induced locomotor activity.
@en
P2093
P2860
P1476
Exendin-4 decreases amphetamine-induced locomotor activity.
@en
P2093
Adeola R Davis
Amanda M Poe
Aurelio Galli
Kevin Erreger
Nigel H Greig
P2860
P304
P356
10.1016/J.PHYSBEH.2012.03.014
P407
P577
2012-03-19T00:00:00Z